[e-drug] Attaran/Gillespie-White and PhRMA patent surveys (cont'd)

[Colleen Fuller <cfuller@telus.net>]

E-drug: Attaran/Gillespie-White and PhRMA patent surveys (cont'd)
-------------------------------------------------------------------------

The assertion that invention is stimulated by patents is not
supported in the Fleming example. The problem that Fleming had
was not the lack of a patent, but the lack of funding. These are two
very different issues, linked mainly and inappropriately by investors
wishing to establish monopolies -- which may lead to a healthy
return on investment, but can hardly be said to stimulate invention.

Colleen Fuller
PharmaWatch Canada
e-mail: cfuller@telus.net


--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Information and archive http://satellife.healthnet.org/programs/edrug.html
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to:  `owner-e-drug@usa.healthnet.org'.